FOLH1 and posterior cortical atrophy: An ongoing multicentre, two-arm, randomised controlled Phase III trial currently recruiting patients, the PRIMARY 2 trial (NCT05154162), will test the additive value of PSMA PET/CT for PCa diagnoses in men with negative or equivocal MRI [41].